Start Time: 16:30 January 1, 0000 5:08 PM ET
OPKO Health, Inc. (NASDAQ:OPK)
Q4 2023 Earnings Conference Call
February 27, 2024, 16:30 PM ET
Company Participants
Phil Frost - Chairman and CEO
Elias Zerhouni - President and Vice Chairman
Adam Logal - SVP and CFO
Charles Bishop - CEO, OPKO Renal
Yvonne Briggs - LHA IR
Conference Call Participants
Jeffrey Cohen - Ladenburg
Maury Raycroft - Jefferies
Edward Tenthoff - Piper Sandler
Yi Chen - H.C. Wainwright & Co.
Operator
Good day, and welcome to the OPKO Health Fourth Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note, this event is being recorded.
I would now like to turn the conference over to Yvonne Briggs. Please go ahead.
Yvonne Briggs
Thank you, operator. Good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss OPKO Health's financial results for the fourth quarter of 2023.
I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking, and as such, will be subject to risks and uncertainties that could materially affect the company's expected results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 2023 and in subsequently filed SEC reports.
This conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, February 27, 2024. Except as required by law, OPKO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.
Before we begin, let me review the format for today's call. Dr. Phillip Frost, Chairman and Chief Executive Officer, will open the call. Dr. Elias Zerhouni, Vice Chairman and President, will then provide an overview of OPKO's pharmaceutical business as well as BioReference Health. After that, Adam Logal, OPKO's CFO, will review the company's fourth quarter financial results, and then we'll open up the call to questions.
Now I'd like to turn the call over to Dr. Frost.
Phil Frost
Good afternoon, and thank you for joining us today. 2023 was a year of significant achievement for OPKO, and we expect continued progress in 2024. In 2023, NGENLA, our long-acting growth hormone therapy, was approved by the FDA for sale in the U.S., the largest growth hormone market in the world.